MATERIALS AND METHODS
Yeast strain constructions. Yeast strains used in this study are listed in Table S1 . Wild-type strain BY4741 or its deletion derivatives were described previously (Winzeler et al, 1999) and purchased from Research Genetics. Myc-tagged strains were generated as described previously (Swanson et al, 2003) , except that myc 13 -tagged cdc73 PCID mutant alleles were introduced by gene replacements using EcoRV fragments of plasmids pHQ1914, pHQ1915, pHQ1963 and pHQ1999 (described below). To construct HQY1379, HQY1414, HQY1441 and HQY1447, spt5∆::HIS3 was first introduced by gene replacement into BY4741 carrying URA3 SPT5 plasmid pMS4; and chromosomal PAF1 in the resultant strain was replaced with PAF1-myc 13 ::kanMX to produce strain H1378. pMS4 was then replaced with pHQ1494 (LEU2 SPT5-HA 3 ), pHQ1876 (LEU2 spt5-S1-15A-HA 3 ), pHQ1894 (LEU2 spt5-S1-15D-HA 3 ) and pHQ1896 (LEU2 spt5-S1-15E-HA 3 ), respectively, by plasmid shuffling.
To construct strains HQY1419, HQY1416, HQY1444 and HQY1449, PAF1 was replaced with PAF1-myc 13 ::HIS3 in bur1-as strain HQY1219 to produce HQY1229. SPT5 was then replaced with spt5∆::natMX by gene replacement in HQY1229 harboring URA3 SPT5 plasmid pMS4, to produce strain HQY1400. Finally, pMS4 was replaced with pHQ1494, pHQ1876, pHQ1894 and pHQ1896, respectively, by plasmid shuffling.
To construct strains HQY1455, HQY1465, HQY1466, HQY1467 and HQY1575, strains BY4741, HQY1379, HQY1441, HQY1447 and HQY1414 were transformed with integrative plasmid pHQ1900 harboring kin28-L83G (kin28-as). The WT allele of KIN28 in the resulting transformants was evicted by counter-selection on 5-FOA medium and the URA3 kin28-as plasmid pSH579 was introduced to compensate for the reduced protein level of kin28-as (Liu et al, 2004) . We verified that growth of the resulting strains is inhibited by NA-PP1 as described previously (Liu et al, 2004) .
To combine cdc73 alleles with spt5-S1-15A, SPT5 in HQY1147, HQY1468, HQY1469 and HQY1471 was replaced with spt5-S1-15A-HA 3 ::kanMX by gene replacement using the EcoRV fragment of plasmid pHQ1993 to produce HQY1508, HQY1509, HQY1510 and HQY1507, respectively. To were introduced into pHQ1690 by PCR as follows. A BlpI-BamHI fragment containing the W380A mutation and a PmlI-HindIII fragment containing the W357A mutation were generated by PCR and used to replace the BlpI-BamHI or PmlI-HindIII fragments of pHQ1690 to produce pHQ1737 and pHQ1739, respectively. Using pHQ1737 as template, a PmlI-HindIII fragment containing W357A,W380A was generated by PCR and used to replace the PmlI-HindIII fragment of pHQ1690 to produce pHQ1738.
Finally, the SacI-HindIII fragments of pHQ1737, pHQ1738 and pHQ1739 were cloned between the SacI and HindIII sites of pRS315 to produce plasmids pHQ1862, pHQ1861 and pHQ1860, respectively. To construct pHQ1952, a BlpI-PvuII and PvuII-BamHI fragment encoding Ala substitutions of Cdc73 residues 304-309 and containing a novel PvuII site was generated by PCR and used to replace the BlpIBamHI fragment of pHQ1862.
SPT5-HA 3 plasmid pHQ1494 was constructed by first cloning the HindIII-KasI fragment of SPT5
obtained from pMS4 between the HindIII and KasI sites of YCplac111 (Gietz & Sugino, 1988) and then 90 bp encoding the 30 amino acids of HA 3 were added to the 3' end of the SPT5 CDS. Construction of spt5-S1-15A-HA 3 , spt5-S1-15D-HA 3 and spt5-S1-15E-HA 3 plasmids was conducted in 4 steps: (1) A MluI-PstI fragment containing S931A and S937A and a PstI-NsiI fragment containing S948A and S958A were generated by PCR and used to replace the MluI-NsiI fragment of pHQ1494 to produce pHQ1869 (spt5-S1-4A-HA 3 ); (2) A SacI-Asp718 fragment containing S987A and S1000A and an Asp718-NsiI fragment containing S1009A and S1015A were produced by PCR and used to replace the SacI-NsiI fragment of pHQ1494 to produce pHQ1868 (spt5-S8-11A-HA 3 ); (3) Using pHQ1868 as template, a SacIStuI (blunt end) fragment containing S987A, S1000A, S1009A, S1015A, S1032A and an Eco47III (blunt end)-NsiI PCR fragment containing S1043A, S1052A and S1058A were generated by PCR and used to replace the SacI-NsiI fragment of pHQ1494 to produce pHQ1870 (spt5-S8-15A-HA 3 ); (4) pHQ1869 (spt5-S1-4A-HA 3 ) was used as template to PCR-amplify a SacI-SspI (blunt end) fragment containing S931A, S937A, S948A, S958A, S969A and S975A, and pHQ1870 (spt5-S8-15A-HA 3 ) served as template to amplify a DraI (blunt end)-NsiI fragment containing S981A, S987A, S1000A, S1009A, S1015A, S1032A, S1043A, S1052A and S1058A, and the resulting SacI-SspI and DraI-NsiI PCR fragments were used to replace the SacI-NsiI fragment of pHQ1494 to produce pHQ1876 (spt5-S1-15A-HA 3 ). Plasmids pHQ1894 (spt5-S1-15D-HA 3 ) and pHQ1896 (spt5-S1-15E-HA 3 ) were constructed in similar ways using primers bearing the corresponding mutations (i.e. Ser to Asp or Glu). To construct pHQ1993, an XbaI-BamHI fragment encoding Spt5 residues 573-1063 and a portion of the HA 3 tag was produced by PCR from pHQ1876, and a BamHI-EcoRV fragment obtained from pFA6a-3HA-kan (Longtine et al, 1998) were cloned into pBS(+KS) and a PmeI-XhoI PCR fragment containing 400 bp of SPT5 3'UTR was inserted into the resulting plasmid to produce pHQ1993.
Antibodies and ATP analogs. The sources of antibodies employed in this study are as follows: monoclonal anti-myc and anti-hemagglutinin (HA) (Roche), anti-Rpb3 (Neoclone), anti-Ser5P (H14; Covance); polyclonal anti-TAP and anti-GST (Open Biosystems), anti-Gcd6 (Cigan et al, 1991) , anti-Rtf1 (Karen Arndt), anti-Spt5 (Grant Hartzog) and anti-Spt5-P (Steven Hahn), anti-H3-K4me 3 (ab8580; abcam), antiH3-K36me 3 (ab9050; abcam) and anti-H3 (ab1791; abcam). ATP analogs 1-NA-PP1 and 3-MB-PP1 for inhibiting kin28-as and bur1-as, respectively, were purchased from Toronto Research Chemicals. Initial studies with 3-MB-PP1 employed analog kindly provided by Kevan Shokat.
Chromatin immunoprecipitation (ChIP) analysis. For experiments examining occupancies at ARG1, overnight saturated cultures were diluted into 100 ml of synthetic complete medium lacking isoleucine and valine (SC-Ilv) to A 600 of ~0.05, cultured for 3 generation to A 600 of ~0.4, and sulfometuron (SM) was added to 1 µg/ml for 30 min to induce Gcn4. For experiments examining occupancies at GAL1, overnight saturated cultures in synthetic complete medium using raffinose as carbon source (SCRaf) were diluted into 100 ml of SCRaf to A 600 of ~0.05, cultured to A 600 of ~0.35, galactose was added to final 2% and incubated for one more hour to induce transcription of GAL1. For uninduced control, cultures were incubated for one more hour without adding galactose. For analog inhibition, 3MB-PP1 was added to final 6 µM for 20 min and then add galactose for one hour. For experiments examining occupancies at PMA1 or ADH1, cells were cultured in SC medium to A 600 of ~0.5.
Cultures were immediately mixed with 10 ml of formaldehyde solution (50 mM HEPES-KOH [pH 7.5], 1 mM EDTA, 100 mM NaCl, 11% formaldehyde) and crosslinked for 20 min at ambient temperature with intermittent shaking, and then quenched with 15 ml 2.5 M glycine. Cells were collected by centrifugation and washed twice with ice-cold Tris-buffered saline (pH 7.5). Cell pellets were suspended in 1 ml FA-lysis buffer (50 mM Hepes-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 1%
Triton X-100, 0.1% sodium deoxycholate, 1 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml Pepstatin A and 10 µg/ml aprotinine ) and sonicated to produce DNA fragments of ~500 bp. Sonicated extracts were centrifuged in a microcentrifuge at full speed for 30 min and the supernatants containing soluble chromatin were used for ChIP experiments as described previously (Swanson et al., 2003) using anti-myc, anti-Rpb3, anti-Ser5P (H14) or anti-HA antibodies. The primer pairs used to amplify sequences of ARG1, GAL1, PMA1, ADH1, or an intergenic sequence from chromosome V (ChrV) are described in Table S3 .
The ChIP data for measuring occupancies of Cdc73-myc (in Fig. 4 ) and at ARG1 under Ile/Val starvation conditions were not normalized for the ChrV signals because we found that the ChrV signal is systematically reduced by cdc73 PCID mutations, spt5-S1-15A, bur1-as, and kin28-as mutations in parallel with the reduced recoveries of ARG1 sequences in the immunoprecipitated chromatin. Since we did not observe this phenomenon in the experiments of Figs. S5, S7, and S8 where we measured Cdc73 or Paf1 occupancies at GAL1, PMA1, and ADH1 for the same mutants, we presume that Paf1C binds to the ChrV sequences under the Ile/Val starvation conditions used to induce Gcn4 but not under the nonstarvation conditions employed in Figs. S5, S7, and S8. Hence, we decided that ChrV is not a valid negative control for non-specific DNA immunoprecipitation when measuring Cdc73 or Paf1 occupancy in Ile/Val-starved cells. Although the ChrV sequence was thought to be untranscribed (Komarnitsky et al, 2000) , a recent high-resolution map of stable unannotated transcripts (SUTs) and cryptic unstable transcripts (CUTs) reveals that the ChrV sequences that we analyzed encompass the 5' end of SUT500 (Xu et al, 2009 ), and we speculate that Paf1C occupies the SUT500 promoter and CDS in Ile/Val starvation conditions. As a result, we chose simply to quantify the IP/input signals for ARG1 CDS from four or more biological replicates (to average out possible fluctuations in IP efficiency from one experiment to the next) and to report the mean IP/input results in the histograms. (A similar problem was encountered previously in ChIP analysis of acetylated H3 in gcn5Δ cells, and addressed in the same manner (Govind et al, 2007) .) Our findings on the effects of cdc73, spt5-S1-15A, bur1-as, and kin28-as mutations on Paf1C recruitment at GAL1, ADH1, and PMA1 were obtained from ChIP data in which the normalization to ChrV sequences was employed. The fact that the overall conclusions for these latter genes are in accordance with those reached at ARG1 supports the validity of our alternative approach for analyzing the ARG1 ChIP data.
Western blot and coimmunoprecipitation analysis. For Western analysis of WCEs, yeast strains were grown in 20 ml of medium under the conditions described above for ChIP assays. WCEs were prepared by the TCA extraction method described previously (Reid & Schatz, 1982) . Aliquots of WCEs were resolved by 3-8% Tris-acetate gel (for Fig. 6A ) or 4-20% SDS-polyacrylamide gel (for Coimmunoprecipitation analysis was conducted as described previously (Zhang et al, 2004) , except using the culture conditions described above for ChIP assays.
Purification of GST fusion proteins and native Cdc73-CBD complexes and Rtf1-CBD. Expression in E. coli BL21 and purification of GST fusion proteins was conducted as described previously (Qiu et al, 1998) . TAP tagged Cdc73 and Rtf1 proteins were purified as follows. Yeast strains F1708 (Open Biosystem's YSC1178-7501935) and HQY1340 were cultured in 2.5 L of yeast extract-peptone-dextrose (YPD) medium to A 600 of ≈3-4 and harvested. Cell pellets were resuspended in one cell pellet volume of lysis buffer (50 mM Tris-HCl [pH7.5], 100 mM NaCl, 1.5 mM MgCl 2 , 0.075% NP-40) and broken with a BeadBeater by beating 30 second 6 times with 2 min interval stopping for cooling. Lysates were clarified to produce WCEs by centrifugation at 15,000 rpm in a Sorvall SS-34 rotor for 30 min. WCEs were added to a 15 ml tube with 1 ml of IgG Sepharose 6 Fast Flow (GE Healthcare) pre-washed 3 times with 10 ml of lysis buffer, and incubated at 4˚C for 2 h with constant rotation. The protein-bound IgG beads were collected in a Beckman J-6 centrifuge at 2000 rpm for 2 min and supernatants were removed. The beads were washed 3 times with 10 ml lysis buffer containing 0.5 mM dithiothreitol (DTT) and transferred to a Poly-Prep column (Bio-Rad) using another 10 ml of the same buffer. After the column was drained, 500 µl of lysis buffer containing 0.5 mM DTT and 100 units of TEV protease (His 6 -tagged AcTEV from Invitrogen) were added and incubated at 20˚C for 2 h with constant rotation. After TEV protease cut, the supernatant was collected by gravity and the beads were washed four times with 500 µl of the same buffer and the supernatants from each wash were collected. All 5 supernatants were pooled (~2.5 ml) and mixed with 500 µl of Ni-NTA agarose beads (Qiagen) at 4˚C for 30 min to remove the His 6 -tagged AcTEV protease. The supernatant was collected, concentrated with a Centricon YM-30 (Millipore) to <1 ml and dialyzed against a buffer of 10 mM Tris-HCl (pH8.0), 50 mM NaCl, 20% glycerol. After dialysis, the concentrated Cdc73-CBD preparations (~500µl) were divided into 100 µl aliquots and stored at -80˚C.
Peptide binding assays. Peptide binding assays were conducted as described previously (Li et al, 2003) .
Biotinylated peptides were purchased from AnaSpec and are listed in Table S4 . 1.5µg of each peptide was bound to 50 µl of streptavidin-coated magnetic beads (Invitrogen) in 100 µl of high salt binding buffer (25 mM Tris-HCl [pH 8.0], 1 M NaCl, 1 mM dithiothreitol, 5% glycerol, 0.03% Nonidet P-40) at 4˚C for 2 h. The peptide-bound beads were washed once with 500 µl of high salt binding buffer, twice with 500 µl of CTD binding buffer (25 mM Tris-HCl [pH 8.0], 50 mM NaCl, 1 mM dithiothreitol, 5% glycerol, 0.03% Nonidet P-40), and resuspended in 100 µl of CTD binding buffer. ~500 ng of recombinant GST fusion proteins purified from E. coli, 30 µl of Cdc73-CBD or Rtf1-CBD purified from yeast were incubated with peptide-bound beads for 1.5 h at 4˚C. The beads were collected magnetically and the supernatants were saved as "unbound fractions". Following three washes with 500 µl each of CTD binding buffer, the protein-bound beads were resuspended in 20 µl of SDS-PAGE loading buffer and, together with input proteins and unbound fractions, subjected to SDS-PAGE and Western analysis with anti-GST or anti-TAP antibodies. For treatment with calf intestine alkaline phosphatase (CIP), after immobilizing the peptides on the beads and washing once with high salt binding buffer and twice with NEBuffer 3 (New England Biolabs), bound peptides were treated with 2.5 units of CIP (New England Biolabs) in 50 µl of NEBuffer 3 at 37˚C for 30 min in the presence or absence of 1x PhosSTOP (Roche).
After treatment with CIP, the supernatants were removed and the beads were washed twice with 500 µl of CTD binding buffer prior to incubation with the appropriate protein fractions for binding assays. Location of each fusion protein in Tris-Glycine gel was confirmed by Western blot using anti-GST antibody (data not shown) and indicated by an asterisk. derive from different portions of the same blot, as described in Fig. S11B . In panel E, lanes 1-3 and 4-7
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derive from different portions of the same blot, as described in Fig. S11C ; whereas lanes 8-18 derive from a separate experiment conducted under identical conditions. ). WCEs were subjected to Western analysis using anti-myc and anti-Gcd6 antibodies, with the later employed to provide a loading control. The 4 lanes each for samples in the last two panels on the right derive from separate portions of the same blots, shown in Fig. S11D , which were produced under the same experimental conditions used to obtain the blots shown in the left-most upper and lower panels of this figure. (B and PAF1-myc 13 bur1-as strains with the indicated SPT5-HA 3 alleles (HQY1416, HQY1444, Y1449 and HQY1419) were employed for all experiments in panels A-C. To measure Paf1-myc occupancies at GAL1 (A), the strains were cultured in SCRaf medium to A 600 of 0.3-0.35 and split into three equal parts.
To one-third, galactose was added to 2% and incubated for 1h to induce GAL1 transcription (-3MB); to the second one-third, cells were treated with 6 µM 3MB-PP1(+3MB) for 20 min to inactivate bur1-as before adding galactose for 1h; for the final one-third incubation in SCRaf was continued for an additional 1h. To determine Paf1-myc binding at PMA1 (B) and ADH1 (C), cells were grown in SC medium to A 600 of 0.3-0.4, and split into two parts. One-half was treated with 6 µM 3MB-PP1(+3MB) for 20 min while the other half was left untreated (-3MB). For ChIP analyses, cells were cross-linked with formaldehyde and subjected to ChIP analysis exactly as described in Fig. S5 using anti-myc antibodies for Paf1-myc or anti-Rpb3 antibodies. Error bars correspond to standard errors of the mean derived from three independent cultures and two independent immunoprecipitations for each culture for GAL1 (A-B), and from two independent cultures and two independent immunoprecipitations for each culture for ADH1
and PMA1 (C-F).
Fig. S8
. Inactivation of kin28-as reduces Paf1-myc occupancy at GAL1 in spt5 phosphomimetic mutants. PAF1-myc 13 strains with the indicated mutations (HQY1379, HQY1465, HQY1466 and HQY1467) were cultured in SCRaf medium to A 600 of 0.3-0.4 and split into three equal parts. To onethird, galactose was added to 2% and incubated for 1h to induce GAL1 transcription (-NA); to the second one-third, cells were treated with 12 µM NA-PP1(+NA) for 12 min to inactivate kin28-as before adding galactose for 1h; for the final one-third incubation in SCRaf was continued for an additional 1h. Cells were cross-linked with formaldehyde and subjected to ChIP analysis exactly as described in Fig. S5 . Error bars correspond to standard errors of the mean derived from three independent cultures and two independent immunoprecipitations for each culture. interactions of PCID residues with the side chains of non-charged residues in the heptad, eg, with Tyr1, Pro3, or Pro6, (ii) H-bonds between PCID residues and main-chain atoms of residues in the heptad, and (iii) multiple salt-bridges and H-bonds between PCID residues and the PO3 = groups on Ser5 or Ser2 of the heptad (Fabrega et al, 2003; Ghosh et al, 2011; Li et al, 2005; Meinhart et al, 2005; Vojnic et al, 2006; Xiang et al, 2010) . (A) We speculate that the Cdc73 PCID might harbor two pCTD docking sites, CDS1
and CDS2, which together contain basic residues (B) arranged in a manner allowing multiple ionic or Hbond interactions with S2P, S5P, and S7P, interspersed with non-charged residues (Z) capable of Van der Waals interactions with side chains of Tyr1, Pro3, and Pro6, or main-chain H-bonds with these 3 residues and also Thr4. Simultaneous contacts of basic residues with S2P and S5P, or with S5P and S7P, would be required for stable pCTD repeat binding. For simplicity, we assume that the binding pockets (blue arcs) are arranged in the PCID to enable interactions with consecutive residues in a single heptad repeat, but they could be spatially separated within the PCID to enable interaction with residues in adjacent heptad repeats (Fabrega et al, 2003) . (B) On binding to an Spt5 pCTR repeat, the same basic residues in CDS1 that contact S2P of the CTD now contact Ser1P in the pCTR hexad, and this latter interaction would be augmented by more extensive Van der Waals or H-bonding interactions with A 2 , W 3 , and Q 6 (of the preceding repeat, colored in blue) of the CTR than are possible with Y 1 , P 3 and T 4 of the CTD heptad.
